Drug discovery, development firm joins Purdue Research Park
June 13, 2013
INDIANAPOLIS - A firm that will carry out drug discovery and development work on medical conditions including cardiovascular disease, diabetes and central nervous system disorders has become a tenant in the Purdue Research Park.
Sunnylife Pharma Inc. was founded by two former Merck & Co. Inc. scientists and an investor in 2012. Zhijian Lu, CEO, said the company will focus on discovering and developing drugs for conditions that its employees have expertise in.
"We stand apart from other drug discovery firms because of our experience," Lu said. "We have several decades of combined experience in drug discovery and development, and our experts have marketed drug or clinical candidates in late clinical trials."
Lu said the company will seek partners in various stages of research and development.
About Sunnylife Pharma Inc.
Sunnylife Pharma Inc. carries out drug discovery research. Working closely with our partner in China, we undergo research in metabolic disorders, CNS diseases, cancer and other diseases that present a serious threat to the human health. Our approach is to focus on a small number of projects at any given time to deliver high quality preclinical candidates with a high probability of success in becoming a commercialized drug.
About Purdue Research Park
The Purdue Research Park has the largest university-affiliated business incubation complex in the country in four locations across Indiana. The parks are home to about 200 companies that employ 4,000 people and are located in West Lafayette, Merrillville, Indianapolis and New Albany.
Purdue Research Park contact: Steve Martin, 765-588-3342, email@example.comSource: Zhijian Lu, firstname.lastname@example.org